EVENTS | VIEW CALENDAR
Bruker inks license agreement with 3M
BREMEN, Germany—Bruker Corp. and 3M Co. have announced the signing of an exclusive patent license agreement that will enable Bruker to include 3M-patented innovations related to matrix-assisted laser desorption ionization (MALDI) mass spectrometry imaging. The patents in question are related to a technique for conducting mass spectrometry analysis on proteins in tissue preserved in paraffin, and the technology makes it easier for researchers to study formalin-fixed, paraffin-embedded (FFPE) tissue in research and drug development. Financial terms were not disclosed.
"We are pleased to license these patents to Bruker, a leader in the field of MALDI imaging, and see this technology applied in the market," Dr. Todd Fruchterman, senior vice president of Research & Development and chief medical officer for 3M Health Care, said in a press release. "We hope that this license agreement will accelerate the research in MALDI imaging of FFPE tissue, and enable it to ultimately become a valuable diagnostic tool."
MALDI imaging originated as a way to analyze fresh, frozen tissue sections, but in recent years has found increasing usage in the analysis of preserved FFPE tissue sections. This technology has seen a jump in usage particularly in tissue sections such as tumor biopsies, and the ability to study molecular phenotypes thanks to MALDI imaging has allowed researchers to correlate such phenotypes with parameters such as disease status or patient outcome.
"FFPE tissue is particularly important for the analysis by MALDI imaging because of the large available archives of such tissue with patient follow-up data and the possibility to use tissue microarrays for the analysis," said Dr. Hartmut Schlüter, professor at the University Medical Center Hamburg-Eppendorf, in a press release. "Furthermore, FFPE tissue is the standard for histopathological diagnosis. Any future diagnostic application of MALDI imaging will likely need to be established on FFPE tissue."
"The interest in the analysis of FFPE tissue by MALDI imaging is increasing strongly," Dr. Sören-Oliver Deininger, market manager for MALDI imaging at Bruker, commented in a statement. "Bruker has developed innovative technology to make MALDI imaging viable in histopathology by the integration of virtual microscopy and the possibility to classify tissue based on the molecular phenotypes (class-imaging). Our license agreement with 3M shows our ongoing commitment to the MALDI imaging field, and gives our customers the necessary freedom to conduct their research and advance the field."
This agreement with 3M is the second MALDI-focused partnership for Bruker in the past two months. The company announced on May 14 an exclusive partnership with SCiLS GmbH centered on the SCiLS Lab software, which enables user-friendly statistical analysis of large MALDI imaging datasets. The financial terms of the agreement were not released.
SOURCE: Bruker press release